5 Stocks Improving Performance Of The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,456 as of Friday, Jan. 3, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,718 issues advancing vs. 1,181 declining with 172 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is unchanged. Top gainers within the industry include Novo Nordisk A/S ( NVO), up 1.2%, Novartis ( NVS), up 0.6%, Sanofi ( SNY), up 0.5% and AstraZeneca ( AZN), up 0.5%. On the negative front, top decliners within the industry include Herbalife ( HLF), down 5.3%, Illumina ( ILMN), down 2.3% and Regeneron Pharmaceuticals ( REGN), down 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Allergan ( AGN) is one of the companies pushing the Drugs industry higher today. As of noon trading, Allergan is up $1.22 (1.1%) to $111.50 on light volume. Thus far, 618,550 shares of Allergan exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $110.69-$112.07 after having opened the day at $110.75 as compared to the previous trading day's close of $110.28.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $33.0 billion and is part of the health care sector. Shares are down 0.7% year to date as of the close of trading on Thursday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, increase in net income and notable return on equity. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Elizabeth Warren Slams Wells Fargo, Equifax: Cramer's Top Takeaways

Centene: Cramer's Top Takeaways

The Pitney Bowes Transformation: Cramer's Top Takeaways

Healthcare Trust of America, Marathon Petroleum: 'Mad Money' Lightning Round

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)